APOGEE THERAPEUTICS INC (APGE) Fundamental Analysis & Valuation

NASDAQ:APGE • US03770N1019

Current stock price

85 USD
+0.83 (+0.99%)
Last:

This APGE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. APGE Profitability Analysis

1.1 Basic Checks

  • In the past year APGE has reported negative net income.
  • APGE had a negative operating cash flow in the past year.
APGE Yearly Net Income VS EBIT VS OCF VS FCFAPGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -27.30%, APGE is in the better half of the industry, outperforming 69.05% of the companies in the same industry.
  • APGE has a better Return On Equity (-28.30%) than 77.18% of its industry peers.
Industry RankSector Rank
ROA -27.3%
ROE -28.3%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APGE Yearly ROA, ROE, ROICAPGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -5 -10 -15 -20 -25

1.3 Margins

  • APGE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APGE Yearly Profit, Operating, Gross MarginsAPGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. APGE Health Analysis

2.1 Basic Checks

  • APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APGE Yearly Shares OutstandingAPGE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
APGE Yearly Total Debt VS Total AssetsAPGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 104.61 indicates that APGE is not in any danger for bankruptcy at the moment.
  • APGE has a better Altman-Z score (104.61) than 98.84% of its industry peers.
  • APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 104.61
ROIC/WACCN/A
WACCN/A
APGE Yearly LT Debt VS Equity VS FCFAPGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 26.57 indicates that APGE has no problem at all paying its short term obligations.
  • APGE has a better Current ratio (26.57) than 97.29% of its industry peers.
  • A Quick Ratio of 26.57 indicates that APGE has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 26.57, APGE belongs to the best of the industry, outperforming 97.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 26.57
Quick Ratio 26.57
APGE Yearly Current Assets VS Current LiabilitesAPGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. APGE Growth Analysis

3.1 Past

  • The earnings per share for APGE have decreased strongly by -28.38% in the last year.
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • APGE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.45% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.6%
EPS Next 2Y-19.69%
EPS Next 3Y-10.25%
EPS Next 5Y7.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APGE Yearly Revenue VS EstimatesAPGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
APGE Yearly EPS VS EstimatesAPGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. APGE Valuation Analysis

4.1 Price/Earnings Ratio

  • APGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APGE Price Earnings VS Forward Price EarningsAPGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APGE Per share dataAPGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as APGE's earnings are expected to decrease with -10.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.69%
EPS Next 3Y-10.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APGE Dividend Analysis

5.1 Amount

  • No dividends for APGE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APGE Fundamentals: All Metrics, Ratios and Statistics

APOGEE THERAPEUTICS INC

NASDAQ:APGE (4/1/2026, 1:54:06 PM)

85

+0.83 (+0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners124.04%
Inst Owner Change12.89%
Ins Owners2.1%
Ins Owner Change-8.73%
Market Cap5.91B
Revenue(TTM)N/A
Net Income(TTM)-255.84M
Analysts86.36
Price Target118.86 (39.84%)
Short Float %17.47%
Short Ratio7.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.39%
Min EPS beat(2)4.31%
Max EPS beat(2)8.47%
EPS beat(4)3
Avg EPS beat(4)8.8%
Min EPS beat(4)-2.92%
Max EPS beat(4)25.36%
EPS beat(8)4
Avg EPS beat(8)2.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.74%
PT rev (3m)19.52%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)-1.72%
EPS NY rev (1m)1.17%
EPS NY rev (3m)-1.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.53
P/tB 6.53
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-5.05
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.27
OCFYN/A
SpS0
BVpS13.01
TBVpS13.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.3%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 362.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.57
Quick Ratio 26.57
Altman-Z 104.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.45%
EPS Next Y-19.6%
EPS Next 2Y-19.69%
EPS Next 3Y-10.25%
EPS Next 5Y7.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.34%
EBIT Next 3Y-21.16%
EBIT Next 5Y-3.87%
FCF growth 1Y-34.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.88%
OCF growth 3YN/A
OCF growth 5YN/A

APOGEE THERAPEUTICS INC / APGE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APGE.


What is the valuation status of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a valuation rating of 0 / 10 to APOGEE THERAPEUTICS INC (APGE). This can be considered as Overvalued.


What is the profitability of APGE stock?

APOGEE THERAPEUTICS INC (APGE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for APGE stock?

The Earnings per Share (EPS) of APOGEE THERAPEUTICS INC (APGE) is expected to decline by -19.6% in the next year.